Standout Papers

The intergroup rhabdomyos... 1988 2026 2000 2013 1988 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. The intergroup rhabdomyosarcoma study-I.A final report
    1988 690 citations Harold M. Maurer, William M. Crist et al. Cancer profile →

Immediate Impact

14 from Science/Nature 56 hit
Sub-graph 1 of 22

Citing Papers

Refining the impact of genetic evidence on clinical success
2024 HitNature
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
2022 Hit
2 intermediate papers

Works of Mohan Beltangady being referenced

A Quantitative Approach for Making Go/No-Go Decisions in Drug Development
2011
A Controlled Trial Comparing Continued Zidovudine with Didanosine in Human Immunodeficiency Virus Infection
1992

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mohan Beltangady 2.2k 990 944 918 692 40 3.0k
Anita Nirenberg 1.8k 0.8× 289 0.3× 828 0.9× 771 0.8× 624 0.9× 43 2.8k
Mark L. Silverman 801 0.4× 613 0.6× 978 1.0× 159 0.2× 956 1.4× 54 3.0k
Tom Powles 655 0.3× 709 0.7× 1.5k 1.6× 217 0.2× 1.1k 1.5× 80 2.7k
James B. Whitmore 721 0.3× 173 0.2× 809 0.9× 749 0.8× 466 0.7× 63 4.0k
Richard S. Neiman 353 0.2× 1.4k 1.4× 1.0k 1.1× 253 0.3× 323 0.5× 80 3.6k
Byron M. Espina 1.0k 0.5× 960 1.0× 1.6k 1.7× 72 0.1× 154 0.2× 73 3.5k
Jacquès Cadranel 642 0.3× 572 0.6× 813 0.9× 185 0.2× 317 0.5× 63 2.0k
Sheila Moore 1.2k 0.6× 320 0.3× 335 0.4× 479 0.5× 582 0.8× 24 2.2k
Elliot Chartash 282 0.1× 477 0.5× 787 0.8× 3.0k 3.2× 224 0.3× 49 4.7k
Harry Grabstald 1.7k 0.8× 209 0.2× 594 0.6× 697 0.8× 2.6k 3.7× 127 4.2k

All Works

Loading papers...

Rankless by CCL
2026